Life Sciences

Health for Life Capital™ Participates in $13.2m Financing of Japanese microbiome leader Anaeropharma Science Innovative, a biotech company that uses live bacteria to fight cancer
5 July 2017

Health for Life Capital™ Participates in $13.2m Financing of Japanese microbiome leader Anaeropharma Science Innovative, a biotech company that uses live bacteria to fight cancer

Paris, France – July 5, 2017 - Seventure Partners, one of Europe’s leaders in financing innovation, and a world-leader in the venture investment in the microbiome sector,...

Read the press release
“Microbes and Me” – how our understanding of the microbiome is pushing new horizons in research and spawning a US$0.5bn+ industry
13 June 2017

“Microbes and Me” – how our understanding of the microbiome is pushing new horizons in research and spawning a US$0.5bn+ industry

Rapidly advancing understanding of the relationship between humans
and their symbiotic microbes, and how their imbalance (dysbiosis) triggers or contributes to...

Read the press release
Innovative Wellbeing Company Skinjay Receives €3.5M from Seventure Partner’s Health for Life Capital
26 January 2017

Innovative Wellbeing Company Skinjay Receives €3.5M from Seventure Partner’s Health for Life Capital

Seventure Partners, one of Europe’s leaders in financing innovation, and a world-leader in the venture investment in the microbiome sector, today announces that from its...

Read the press release
Enterome starts Phase I clinical trial with its lead candidate EB8018 to treat Crohn’s disease
5 January 2017

Enterome starts Phase I clinical trial with its lead candidate EB8018 to treat Crohn’s disease

Enterome SA, a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, is pleased to announce the launch of a Phase 1 clinical study with its...

Read the press release
MaaT Pharma announces first positive DSMB safety review and continuation of its Phase 1b ODYSSEE study
17 November 2016

MaaT Pharma announces first positive DSMB safety review and continuation of its Phase 1b ODYSSEE study

MaaT Pharma ODYSSEE Study focuses in prevention of dysbiosis complications with autologous fecal microbiota transplantation in Acute Myeloid Leukemia patients undergoing...

Read the press release
MaaT Pharma Unveils the First GMP-Compliant European Fecal Microbiota Transfer Platform
16 November 2016

MaaT Pharma Unveils the First GMP-Compliant European Fecal Microbiota Transfer Platform

Major treatments such as high-dose antibiotic therapies and chemotherapies can lead to serious complications and create a gut microbiota imbalance (formerly called intestinal...

Read the press release
Bristol-Myers Squibb and Enterome SA Announce Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Drug Targets and Bioactive Molecules
16 November 2016

Bristol-Myers Squibb and Enterome SA Announce Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Drug Targets and Bioactive Molecules

Bristol-Myers Squibb (NYSE: BMY) and Enterome SA (Enterome), a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, announced that they...

Read the press release
Advanced Accelerator Applications Announces Swiss Marketing Authorization for Two PET Diagnostic Products
2 November 2016

Advanced Accelerator Applications Announces Swiss Marketing Authorization for Two PET Diagnostic Products

Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in molecular nuclear medicine, announced today that the...

Read the press release
Enterome raises €14.5 million in Series C financing round Nestlé Health Science invests alongside existing investors
20 April 2016

Enterome raises €14.5 million in Series C financing round Nestlé Health Science invests alongside existing investors

ENTEROME Bioscience SA, a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, announces that it has raised €14.5 million in a Series C...

Read the press release
TargEDys develops new microbiome-based solutions for appetite regulation and announces a €5.8M international round of financing to demonstrate product clinical efficacy.
14 April 2016

TargEDys develops new microbiome-based solutions for appetite regulation and announces a €5.8M international round of financing to demonstrate product clinical efficacy.

TargEDys, an innovator in appetite regulation, announces a €5.8M “Series A” fundraising round based on world-leading research from company founders Serguei Fetissov and...

Read the press release